艾滋病毒感染者中 SARS-CoV-2 感染和 COVID-19 疾病的流行率、风险因素和替诺福韦治疗的影响。一项基于人群的横断面研究。

IF 4.8 2区医学 Q1 INFECTIOUS DISEASES

International Journal of Infectious Diseases Pub Date : 2024-10-18 DOI:10.1016/j.ijid.2024.107266

Elisa de Lazzari , Daniel K. Nomah , Jose L. Blanco , Naira Rico , Xabier Filella , Natalia Egri , Raquel Ruiz , Maria Angeles Marcos , Maria del Mar Mosquera , Jose Alcamí , Sonsoles Sánchez-Palomino , Andreu Bruguera , Carmen Hurtado , Cristina Rovira , Juan Ambrosioni , Iván Chivite , Ana González-Cordón , Alexy Inciarte , Montserrat Laguno , María Martínez-Rebollar , Jose M. Miro

{"title":"艾滋病毒感染者中 SARS-CoV-2 感染和 COVID-19 疾病的流行率、风险因素和替诺福韦治疗的影响。一项基于人群的横断面研究。","authors":"Elisa de Lazzari , Daniel K. Nomah , Jose L. Blanco , Naira Rico , Xabier Filella , Natalia Egri , Raquel Ruiz , Maria Angeles Marcos , Maria del Mar Mosquera , Jose Alcamí , Sonsoles Sánchez-Palomino , Andreu Bruguera , Carmen Hurtado , Cristina Rovira , Juan Ambrosioni , Iván Chivite , Ana González-Cordón , Alexy Inciarte , Montserrat Laguno , María Martínez-Rebollar , Jose M. Miro","doi":"10.1016/j.ijid.2024.107266","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>The prevalence and risk factors of SARS-CoV-2 infection among unvaccinated people living with HIV (PWH) are not well understood, and the protective role of tenofovir remains controversial. This study aimed to assess the SARS-CoV-2 prevalence and associated risk factors among unvaccinated PWH, and to evaluate the impact of tenofovir.</div></div><div><h3>Methods</h3><div>We conducted as a cross-sectional study between November 2020 and May 2021. Plasma samples from 4,400 of 5,476 PWH were tested for total antibodies, IgG, IgM, and IgA.</div></div><div><h3>Results</h3><div>Among the participants (median age 48 years, 84% male), 92% had undetectable HIV viral loads and 5% had syphilis. The prevalence of SARS-CoV-2 infection was 18% (95% CI 17-19), with 1,180 individuals showing antibodies (IgG 13%, IgA 10%, IgM 11%). Of those seropositive for SARS-CoV-2, 67.5% were asymptomatic, 29% had mild disease, and 3.5% had severe/critical conditions. Risk factors included younger age, being female, men who have sex with men (MSM) status, non-European origin, and a history of syphilis. Neither antiretrovirals nor tenofovir provided protection against SARS-CoV-2 infection or COVID-19 disease.</div></div><div><h3>Conclusion</h3><div>Ongoing surveillance and tailored interventions are crucial for at-risk PWH amid evolving SARS-CoV-2 variants. Tenofovir did not prevent SARS-CoV-2 infection or COVID-19.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"149 ","pages":"Article 107266"},"PeriodicalIF":4.8000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence, risk factors and the impact of tenofovir treatment in SARS-CoV-2 infection and COVID-19 disease among people living with HIV: A cross-sectional population-based study\",\"authors\":\"Elisa de Lazzari , Daniel K. Nomah , Jose L. Blanco , Naira Rico , Xabier Filella , Natalia Egri , Raquel Ruiz , Maria Angeles Marcos , Maria del Mar Mosquera , Jose Alcamí , Sonsoles Sánchez-Palomino , Andreu Bruguera , Carmen Hurtado , Cristina Rovira , Juan Ambrosioni , Iván Chivite , Ana González-Cordón , Alexy Inciarte , Montserrat Laguno , María Martínez-Rebollar , Jose M. Miro\",\"doi\":\"10.1016/j.ijid.2024.107266\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>The prevalence and risk factors of SARS-CoV-2 infection among unvaccinated people living with HIV (PWH) are not well understood, and the protective role of tenofovir remains controversial. This study aimed to assess the SARS-CoV-2 prevalence and associated risk factors among unvaccinated PWH, and to evaluate the impact of tenofovir.</div></div><div><h3>Methods</h3><div>We conducted as a cross-sectional study between November 2020 and May 2021. Plasma samples from 4,400 of 5,476 PWH were tested for total antibodies, IgG, IgM, and IgA.</div></div><div><h3>Results</h3><div>Among the participants (median age 48 years, 84% male), 92% had undetectable HIV viral loads and 5% had syphilis. The prevalence of SARS-CoV-2 infection was 18% (95% CI 17-19), with 1,180 individuals showing antibodies (IgG 13%, IgA 10%, IgM 11%). Of those seropositive for SARS-CoV-2, 67.5% were asymptomatic, 29% had mild disease, and 3.5% had severe/critical conditions. Risk factors included younger age, being female, men who have sex with men (MSM) status, non-European origin, and a history of syphilis. Neither antiretrovirals nor tenofovir provided protection against SARS-CoV-2 infection or COVID-19 disease.</div></div><div><h3>Conclusion</h3><div>Ongoing surveillance and tailored interventions are crucial for at-risk PWH amid evolving SARS-CoV-2 variants. Tenofovir did not prevent SARS-CoV-2 infection or COVID-19.</div></div>\",\"PeriodicalId\":14006,\"journal\":{\"name\":\"International Journal of Infectious Diseases\",\"volume\":\"149 \",\"pages\":\"Article 107266\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1201971224003370\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1201971224003370","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

在未接种疫苗的艾滋病病毒感染者（PWH）中，SARS-CoV-2 的感染率和风险因素尚不十分清楚，而替诺福韦的保护作用仍存在争议。本研究旨在评估未接种疫苗的艾滋病病毒感染者中的 SARS-CoV-2 感染率和相关风险因素，并评估替诺福韦的影响。我们在 2020 年 11 月至 2021 年 5 月期间进行了一项横断面研究。对5476名PWH中4400名的血浆样本进行了总抗体、IgG、IgM和IgA检测。在参与者（中位年龄 48 岁，84% 为男性）中，92% 的人检测不到 HIV 病毒载量，5% 的人患有梅毒。SARS-CoV-2 感染率为 18%（95% CI 17-19），有 1180 人出现抗体（IgG 13%、IgA 10%、IgM 11%）。在 SARS-CoV-2 血清阳性者中，67.5%无症状，29%病情轻微，3.5%病情严重/危急。风险因素包括年龄较小、女性、男男性行为者（MSM）身份、非欧洲血统以及梅毒病史。抗逆转录病毒药物和替诺福韦都不能预防 SARS-CoV-2 感染或 COVID-19 疾病。在SARS-CoV-2变种不断演变的情况下，持续监测和有针对性的干预措施对高危公共卫生人员至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prevalence, risk factors and the impact of tenofovir treatment in SARS-CoV-2 infection and COVID-19 disease among people living with HIV: A cross-sectional population-based study

Objectives

The prevalence and risk factors of SARS-CoV-2 infection among unvaccinated people living with HIV (PWH) are not well understood, and the protective role of tenofovir remains controversial. This study aimed to assess the SARS-CoV-2 prevalence and associated risk factors among unvaccinated PWH, and to evaluate the impact of tenofovir.

Methods

We conducted as a cross-sectional study between November 2020 and May 2021. Plasma samples from 4,400 of 5,476 PWH were tested for total antibodies, IgG, IgM, and IgA.

Results

Among the participants (median age 48 years, 84% male), 92% had undetectable HIV viral loads and 5% had syphilis. The prevalence of SARS-CoV-2 infection was 18% (95% CI 17-19), with 1,180 individuals showing antibodies (IgG 13%, IgA 10%, IgM 11%). Of those seropositive for SARS-CoV-2, 67.5% were asymptomatic, 29% had mild disease, and 3.5% had severe/critical conditions. Risk factors included younger age, being female, men who have sex with men (MSM) status, non-European origin, and a history of syphilis. Neither antiretrovirals nor tenofovir provided protection against SARS-CoV-2 infection or COVID-19 disease.

Conclusion

Ongoing surveillance and tailored interventions are crucial for at-risk PWH amid evolving SARS-CoV-2 variants. Tenofovir did not prevent SARS-CoV-2 infection or COVID-19.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Infectious Diseases 医学-传染病学

CiteScore

18.90

自引率

2.40%

发文量

1020

审稿时长

30 days

期刊介绍： International Journal of Infectious Diseases (IJID) Publisher: International Society for Infectious Diseases Publication Frequency: Monthly Type: Peer-reviewed, Open Access Scope: Publishes original clinical and laboratory-based research. Reports clinical trials, reviews, and some case reports. Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases. Emphasizes diseases common in under-resourced countries.